에 대한 최신 뉴스 Medtronic (NYSE:MDT) 주식

Medtronic

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

The Memorandum On China

News

Economics

Markets

Tech

Media

AAPL

일요일(23일) 허리펑 중국 부총리는 애플(NASDAQ:AAPL), 화이자(NYSE:PFE), 마스터카드(NYSE:MA), 일라이 릴리(NYSE:LLY), 카길(Cargill ) 등 주요 기업들의 최고 경영자들과 만났다.

중국, 미국과 긴장 속 애플·화이자·일라이릴리 등 주요 기업 경영진과 만나...&#34;계속 비즈니스 환경 개선할 것&#34;

Market,Sentiment,,Fear,And,Greed,Index,,Emotional,On,Stock,Market

Earnings

Pre-Market Outlook

Trading Ideas

NVDA

SERV

SOUN

CNN 머니 공포·탐욕 지수는 전체 시장 심리의 개선을 나타냈으며 지난 금요일(14일) &#34;공포&#34; 영역에 있었다.

다우 지수 150p 이상 하락했으나 주간 상승 기록: 투자 심리 개선, 탐욕 지수는 &#39;공포&#39; 영역

BIDU

SOHU

화요일(18일) 아침 미국 주식 선물이 상승하는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식들은 다음과 같다. 메드트로닉, 바이두, 소후닷컴, 플루오르 및 옥시덴탈 페트롤리엄

화요일 주목해야 할 주식: 메드트로닉, 바이두, 소후닷컴, 플루오르 및 옥시덴탈 페트롤리엄

Medtronic PLC

Measurable Data Token - United States Dollar

MEDIA TECHS INC by Media Technologies Inc.

Media Technologies Inc

MEDIA TEK INC by Media Tek Inc.

MANDATUM OYJ U/ADR by MANDATUM OYJ

MediaTek Inc

MEDITERRANEAN TOWERS LTD by Mediterranean Towers LTD

Mediterranean Towers Ltd

Reported Sunday, Medtronic Evolut TAVR Demonstrates Sustained Valve Performance And Lower Cardiovascular Mortality Trend At 5 Years

On Sunday, Chinese Vice Premier He Lifeng met with top executives from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Cargill, and other major firms.
What Happened: "China will continue to improve the business environment and welcome more investment by multinational companies in China, sharing opportunities for development," he told the leaders, describing the country's economy as "highly resilient" and "full of vitality."
Executives from medical device maker Medtronic PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and investment management firm Conning were also in attendance, reported Reuters, citing a statement from China's Ministry of Commerce.
However, the statement did not specify where the meeting took place.
Many of the executives are in Beijing to attend the China Development Forum, where further high-level meetings, including a possible session with President Xi Jinping, are expected later this week, the report noted, citing unnamed sources.
See Also:&nbsp;<a href="https://www.benzinga.com/25/03/44272657/alibaba-chairperson-says-everyone-is-concerned-about-tariffs-as-he-expects-levies-on-chinese-evs" target="_blank" rel="noreferrer noopener">Alibaba's Joseph Tsai Says ‘Everyone Is Concerned About Tariffs,' As He Expects Levies On Chinese EVs</a>
Why It's Important: Beijing has ramped up efforts to attract foreign capital amid a slowing economy and fresh <a href="https://in.benzinga.com/news/global/25/03/44448798/china-ponders-export-limitations-to-quell-trumps-trade-onslaught">U.S. tariff headwinds</a> under President Donald Trump.
While American companies made up the largest group at this year's forum, sources say fewer U.S. CEOs attended compared to last year—signaling ongoing caution in cross-border corporate relations, the report noted.
Previously, the Chinese President expressed concerns about the possibility of China facing isolation similar to the Soviet Union during the Cold War. The ongoing trade war has heightened <a href="https://in.benzinga.com/25/03/44161587/is-china-apprehensive-of-losing-the-trade-war-to-the-us-china-could-get-isolated-like-moscow-fears-xi-jinping">fears of economic isolation</a>.
 Despite these challenges, <a href="https://in.benzinga.com/general/market-summary/25/03/44273552/ray-dalio-says-china-is-way-ahead-in-ai-and-robotics-us-lags-in-mass-production">China remains a leader</a> in technological advancements, particularly in artificial intelligence and robotics, according to investor Ray Dalio.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/44055314/mrbeast-lost-millions-on-amazons-beast-games-now-hes-looking-to-raise-hundreds-of-millions-to-take-h" target="_blank" rel="noreferrer noopener">MrBeast Lost Millions On Amazon's ‘Beast Games'—Now He's Looking To Raise Hundreds Of Millions To Take His Brand To The Next Level</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment'

High-rolling investors have positioned themselves bullish on Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MDT often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Medtronic. This is not a typical pattern.
The sentiment among these major traders is split, with 62% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $38,125, and 7 calls, totaling $895,860.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $82.5 to $92.5 for Medtronic over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Medtronic's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Medtronic's whale activity within a strike price range from $82.5 to $92.5 in the last 30 days. 
<h3>Medtronic 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742576490_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.35</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$85.00</td>
<td>$287.2K</td>
<td>4.0K</td>
<td>1.9K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.0</td>
<td>$3.85</td>
<td>$3.85</td>
<td>$90.00</td>
<td>$220.6K</td>
<td>1.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$87.50</td>
<td>$205.2K</td>
<td>419</td>
<td>390</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.45</td>
<td>$4.35</td>
<td>$4.35</td>
<td>$87.50</td>
<td>$54.8K</td>
<td>588</td>
<td>126</td>
</tr>
<tr>
<td>MDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$1.94</td>
<td>$1.8</td>
<td>$1.84</td>
<td>$90.00</td>
<td>$48.1K</td>
<td>916</td>
<td>409</td>
</tr>
</tbody>
</table>

<h3>About Medtronic</h3>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Following our analysis of the options activities associated with Medtronic, we pivot to a closer look at the company's own performance.
<h3>Current Position of Medtronic</h3>
<ul>
<li>With a trading volume of 3,457,096, the price of MDT is down by -0.69%, reaching $90.59.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 62 days from now.</li>
</ul>
<h3>Expert Opinions on Medtronic</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $107.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Citigroup upgrades its rating to Buy with a revised price target of $107. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Medtronic, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Looking At Medtronic's Recent Unusual Options Activity

<a href="https://www.fda.gov/medical-devices/medical-device-recalls/embolization-device-recall-and-correction-medtronic-removes-unused-027-compatible-pipeline-vantage#:~:text=Medical%20Device%20Recalls-,Embolization%20Device%20Recall%20and%20Correction%3A%20Medtronic%20Removes%20Unused%20027%20Compatible,Wall%20Apposition%20and%20Braid%20Deformation" title="https://www.fda.gov/medical-devices/medical-device-recalls/embolization-device-recall-and-correction-medtronic-removes-unused-027-compatible-pipeline-vantage#:~:text=Medical%20Device%20Recalls-,Embolization%20Device%20Recall%20and%20Correction%3A%20Medtronic%20Removes%20Unused%20027%20Compatible,Wall%20Apposition%20and%20Braid%20Deformation">https://www.fda.gov/medical-devices/medical-device-recalls/embolization-device-recall-and-correction-medtronic-removes-unused-027-compatible-pipeline-vantage#:~:text=Medical%20Device%20Recalls-,Embolization%20Device%20Recall%20and%20Correction%3A%20Medtronic%20Removes%20Unused%20027%20Compatible,Wall%20Apposition%20and%20Braid%20Deformation</a>

Biotech

General

FDA Says Medtronic Removes Unused 027 Compatible Pipeline Vantage Embolization Device With Shield Technology; Medtronic Updates Use Instructions For 021 Compatible Pipeline Vantage Embolization Devices; Medtronic Updates Instructions For Using Pipeline Vantage 021 Device Models Due To Risk Of Incomplete Wall Apposition & Braid Deformation

CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial&nbsp;to primarily enroll women using the two most widely used global TAVR devices

Reported Sunday, Medtronic Evolut TAVR Demonstrates Superior Durability And Valve Function In Small Annulus Patients, SMART Trial Shows

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>DA Davidson analyst Rudy Kessinger upgraded the rating for Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Neutral to Buy and raised the price target from $90 to $125. Okta shares closed at $87.16 on Monday. <a href="https://www.benzinga.com/quote/okta/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Aman Rakkar upgraded the rating for HSBC Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSBC#NYSE">HSBC</a>) from Equal-Weight to Overweight. HSBC shares closed at $60.33 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Joanne Wuensch upgraded Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Neutral to Buy and raised the price target from $92 to $107. Medtronic shares closed at $94.30 on Monday. <a href="https://www.benzinga.com/quote/mdt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Julien Dumoulin-Smith upgraded The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) from Underperform to Neutral and raised the price target from $11 to $13. AES shares closed at $11.19 on Monday. <a href="https://www.benzinga.com/quote/aes/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Jeffrey Hammond upgraded the rating for Nordson Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) from Sector Weight to Overweight and maintained the price target of $260. Nordson shares closed at $207.10 on Monday. <a href="https://www.benzinga.com/quote/ndsn/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3"> Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Upgrades

Price Target

Analyst Ratings

HSBC

NDSN

OKTA

This Medtronic Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Throughout the last three months, 5 analysts have evaluated Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Medtronic and provided 12-month price targets. The average target is $97.4, accompanied by a high estimate of $107.00 and a low estimate of $89.00. Witnessing a positive shift, the current average has risen by 4.73% from the previous average price target of $93.00.
<img src="https://www.benzinga.com/files/images/story/2025/1741093276_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Medtronic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$91.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$89.00</td>
<td>$93.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Medtronic. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Medtronic's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Medtronic analyst ratings.</a>
<h2>Delving into Medtronic's Background</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Unraveling the Financial Story of Medtronic</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Medtronic's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.51% as of 31 January, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 15.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Medtronic's ROE stands out, surpassing industry averages. With an impressive ROE of 2.64%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Medtronic's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.44% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.54, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Medtronic's Future

Citigroup analyst Joanne Wuensch upgrades Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Neutral to Buy and raises the price target from $92 to $107.

Citigroup Upgrades Medtronic to Buy, Raises Price Target to $107

On Monday, the FDA approved Medtronic plc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43911731/medtronic-earns-u-s-fda-approval-for-the-worlds-first-adaptive-deep-brain-stimulation-system-for-p" rel="noreferrer noopener">with Parkinson&#8217;s disease</a>.
Deep brain stimulation uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.
Medtronic has enhanced its Percept DBS neurostimulators with exclusive BrainSense Adaptive technology for Parkinson&#8217;s.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43782957/medtronic-q3-earnings-cardiovascular-and-neuroscience-drive-growth-surgical-revenue-dips-reaffirms-annual-forecast" rel="noreferrer noopener">Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast</a>
This feature personalizes therapy based on a patient&#8217;s brain activity in real-time – both in clinical settings and daily life.
It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.
BrainSense Adaptive DBS is available to Medtronic DBS patients with Parkinson&#8217;s who have been implanted with a Percept neurostimulator and future Medtronic DBS patients.
The Medtronic Adaptive DBS Algorithm for Personalized Therapy in Parkinson&#8217;s Disease (ADAPT-PD) trial highlights the potential of aDBS in clinical practice.
The FDA approval also includes the Medtronic BrainSense Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings. Using EI, clinicians can conduct an accurate and precise initial programming, 85% faster than traditional electrode selection.
BrainSense aDBS and EI are also&nbsp;available&nbsp;in&nbsp;Europe. Patient programs in&nbsp;the United States&nbsp;will begin at select healthcare systems over the coming weeks, with availability nationwide in the coming months.
Price Action: MDT stock is up 0.85% at $90.70 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43910982/apple-commits-500-billion-in-us-investment-for-ai-push-boost-us-manufacturing-tech" target="_blank" rel="noreferrer noopener">Apple Commits $500 Billion In US Investment For AI Push, Boost US Manufacturing Tech</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

FDA Approves Medtronic's Adaptive Deep Brain Stimulation System For Parkinson's Patients

New closed-loop system self-adjusts DBS therapy to individual brain activity&nbsp;in real time; the largest commercial launch of brain-computer interface technology ever&nbsp;
GALWAY, Ireland, Feb. 24, 2025 /PRNewswire/ --&nbsp;For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense&#x2122; Adaptive deep brain stimulation (aDBS) and BrainSense&#x2122; Electrode Identifier (EI).
There is no cure for debilitating neurological conditions like Parkinson's, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders.
Now Medtronic has enhanced its Percept&#x2122; DBS neurostimulators with exclusive BrainSense&#x2122; Adaptive technology†, introducing aDBS for people living with Parkinson's. This feature personalizes therapy based on a patient's brain activity in real time – both in clinical settings and in daily life2. It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation.

Medtronic Earns U.S. FDA Approval For The World's First Adaptive Deep Brain Stimulation System For People With Parkinson's

RBC Capital analyst Shagun Singh reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Outperform and maintains $105 price target.

Reiteration

RBC Capital Reiterates Outperform on Medtronic, Maintains $105 Price Target

UBS analyst Danielle Antalffy maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and raises the price target from $85 to $95.

UBS Maintains Neutral on Medtronic, Raises Price Target to $95

Baird analyst David Rescott maintains Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) with a Neutral and raises the price target from $90 to $91.

Baird Maintains Neutral on Medtronic, Raises Price Target to $91

Needham analyst Mike Matson reiterates Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from Hold to Hold.

Needham Reiterates Hold on Medtronicto Hold

Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC<a href="https://www.benzinga.com/25/02/43784079/us-stocks-mixed-ny-state-business-activity-rises-in-february"> minutes on Wednesday.</a>
U.S. and Russian officials met in Saudi Arabia Tuesday <a href="https://www.benzinga.com/news/global/25/02/43787369/us-russian-officials-begin-ukraine-peace-talks-defense-sector-stocks-rise">to begin</a> peace negotiations, marking their first high-level talks on the war in Ukraine since Russia&#8217;s invasion in 2022. The initial talks were intended as "trust-building" and could lay the groundwork for a future meeting between President Donald Trump and Russian President Vladimir Putin. Ukrainian and other European officials were notably absent from Tuesday's discussions. 
WTI crude oil futures held steady as diplomatic talks between the U.S. and Russia raised hopes for reduced geopolitical risks. 
Read Next: <a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a>
The yield on the 10-year US Treasury note rose 0.04%, back above the 4.5% threshold as investors digested recent comments from Fed officials, including Christopher Waller, Michelle Bowman and Patrick Harker, which reinforced expectations that interest rates will remain on hold in the near term.  
All eyes will be on Wednesday's release of the latest FOMC's minutes set for 2 p.m. ET. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 0.57% to $88.64.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was down 1.16% to $94,672 as crypto markets fell broadly Tuesday.&nbsp;&nbsp;
<h2 class="wp-block-heading">Tuesday's Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,000.73</td>
<td>-0.12%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,115.46</td>
<td>0.01%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,454.56</td>
<td>-0.19%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,288.09</td>
<td>0.36%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched up 0.1% to $610.31.&nbsp;</li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.17% at $445.03.&nbsp;</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.04% to $538.36.&nbsp;</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.44% to $226.97.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) dipped 0.53% to $225.81.&nbsp;</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) rose 0.95% to $90.93.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Tuesday's Stock Movers:&nbsp;</h2>
Shares of Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) surged following reports suggesting Broadcom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Taiwan Semiconductor Manufacturing Co. Ltd.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) are <a href="https://www.benzinga.com/markets/equities/25/02/43775200/intel-jumps-over-5-in-tuesday-pre-market-as-deal-talks-with-broadcom-and-tsmc-surface">considering bids</a> for portions of the company.
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Baidu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)&nbsp;</li>
<li>Constellation Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>)&nbsp;</li>
<li>Franklin Electric Co., Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FELE#NASDAQ">FELE</a>)&nbsp;</li>
<li>Watsco, Inc.&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>)&nbsp;</li>
<li>Axsome Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>)&nbsp;</li>
<li>Donnelley Financial Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFIN#NYSE">DFIN</a>)&nbsp;</li>
<li>Fluor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>)&nbsp;</li>
<li>Medtronic Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)&nbsp;</li>
<li>GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>)&nbsp;</li>
<li>Entergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>)&nbsp;</li>
<li>iQIYI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>)&nbsp;</li>
</ul>
Companies reporting after Tuesday's closing bell include:&nbsp;
<ul>
<li>Occidental Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>)&nbsp;</li>
<li>Matador Resources Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>)&nbsp;</li>
<li>Devon Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>)&nbsp;</li>
<li>Bumble, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>)&nbsp;</li>
<li>Sonoco Products Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>)&nbsp;</li>
<li>Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>)&nbsp;</li>
<li>Star Bulk Carriers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBLK#NASDAQ">SBLK</a>)&nbsp;</li>
<li>Shift4 Payments, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>)&nbsp;</li>
<li>Matador Resources Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/02/43732115/explosion-rocks-chernobyl-nuclear-site-as-zelenskyy-signals-readiness-for-peace-talks">Explosion Rocks Chernobyl Nuclear Site As Zelenskyy Signals Readiness For Peace Talks</a>&nbsp;</li>
</ul>
Image: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Market Summary

Broad U.S. Equity ETFs

Commodities

Global

Federal Reserve

Movers

ETFs

$BTC

AVGO

AXSM

BMBL

DFIN

SPDR Dow Jones Industrial Average ETF Trust

FELE

FOUR

INTC

MTDR

SBLK

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?

Tuesday,&nbsp;Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported third-quarter 2025 sales of $8.29 billion, missing the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $8.32 billion</a>.
The medical device maker reported adjusted EPS of $1.39, beating the consensus of $1.36. Revenue increased 2.5% year over year, as reported,&nbsp;and 4.1% organically.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/42859544/anteris-technologies-positioned-to-capture-4-5-of-us-transcatheter-valve-replacement-market-by-2030-analyst" rel="noreferrer noopener">Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst</a>
&#8220;We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth,&#8221; said&nbsp;Geoff Martha, Medtronic chairman and chief executive officer.
&#8220;We are starting to see the results from our long-term investments in groundbreaking innovation, such as pulsed-field ablation, to drive growth in some of the most attractive markets in MedTech.&#8221;
Cardiovascular segment revenue reached&nbsp;$3.04 billion, up 3.7% year over year as reported, and&nbsp;increased 5% organically, with mid-single digit increases in Cardiac Rhythm &amp; Heart Failure and Structural Heart &amp; Aortic and a low-single-digit increase in Coronary &amp; Peripheral Vascular, all on <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43776497/medtronic-reports-third-quarter-fiscal-2025-financial-results" rel="noreferrer noopener">an organic basis</a>.
Neuroscience revenues of&nbsp;$2.46 billion&nbsp;increased 4.4% as reported and 5.2% organically, with a low-double-digit increase in Neuromodulation, mid-single-digit increase in Cranial &amp; Spinal Technologies, and low-single-digit increase in Specialty Therapies, all on an organic basis.
Medical Surgical revenue of $2.07 billion decreased by 1.9% as reported and by 0.4% organically, with flat organic results in Surgical &amp; Endoscopy and a low-single-digit organic decline in Acute Care &amp; Monitoring.
Diabetes revenue of&nbsp;$694 million&nbsp;increased by 8.4%, as reported, and by 10.4% organic.
Guidance:&nbsp;Medtronic reaffirms its fiscal year 2025 organic revenue <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/42069216/medtronic-q2-earnings-diabetes-and-neuroscience-revenue-boost-growth-raises-annual-outlook" rel="noreferrer noopener">growth guidance of 4.75%-5%</a>.
If recent foreign currency exchange rates hold, FY25 revenue growth would be around 3.4%-3.8%. If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%.
Medtronic expects 2025 adjusted EPS of $5.44-$5.50 versus consensus of $5.45.
Price Action: MDT stock is down 5.94% at $87.30 during the premarket session at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43778628/fda-approves-gsks-5-in-1-meningococcal-vaccine-for-adolescents-ahead-of-cdc-advisory-committee-vote-meeting-next-week" target="_blank" rel="noreferrer noopener">FDA Approves GSK&#8217;s 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week</a></li>
</ul>
Photo via Shutterstock

Guidance

Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast

CORRECTION: Medtronic Affirms FY25 Adj EPS Outlook of $5.44-$5.50 vs $5.45 Estimate; Narrows FY25 Sales Guidance from $33.46B-$33.63B To $33.46B-$33.59B vs $33.54B Estimate

WIIM

Medtronic shares are trading lower after the company reported mixed Q3 financial results and issued FY25 adjusted EPS guidance below estimates.

Medtronic Reaffirms Its FY25 Organic Revenue Growth Guidance Of 4.75%-5%

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported quarterly earnings of $1.39 per share which beat the analyst consensus estimate of $1.36 by 2.21 percent. This is a 6.92 percent increase over earnings of $1.30 per share from the same period last year. The company reported quarterly sales of $8.29 billion which missed the analyst consensus estimate of $8.32 billion by 0.39 percent. This is a 2.51 percent increase over sales of $8.09 billion the same period last year.

Medtronic Q3 2025 Adj EPS $1.39 Beats $1.36 Estimate, Sales $8.29B Miss $8.32B Estimate

Management

Press Releases

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Medtronic to announce financial results for its third quarter of fiscal year 2025

Medtronic reports third quarter fiscal 2025 financial results

Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's

Dividends

Medtronic announces cash dividend for fourth quarter of fiscal year 2025

SMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients

CGS Transforms Workplace Training with Cicero,  a New AI-Driven, Customizable Roleplay Platform

Artificial Intelligence Influence on Healthcare Industry Reaching All Time Highs for Diagnostics and Treatments

Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

ACON

AVAI

OBIO

TDOC

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Citigroup

RBC Capital

Baird

Truist Securities

Screenshot 2024-10-03 at 5.30.47 PM

DXCM

GCTK

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

일요일(23일) 허리펑 중국 부총리는 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), 마스터카드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), 일라이 릴리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), 카길(Cargill ) 등 주요 기업들의 최고 경영자들과 만났다.
무슨 일 있었나: 허리펑 부총리는 "중국은 지속적으로 비즈니스 환경을 개선하고 다국적 기업의 중국 내 더 많은 투자를 환영하며 발전 기회를 공유할 것&#8221;이라고 말하고, 중국 경제를 ‘매우 탄력적'이고 ‘활력이 넘친다'고 설명했다.
로이터 통신은 중국 상무부의 성명을 인용해 의료 기기 제조업체인 메드트로닉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)과 투자 관리 회사 코닝(Conning)의 임원들도 참석했다고 보도했다.
그러나 성명서에는 회의가 어디서 열렸는지는 명시되지 않았다.
해당 보도는 익명의 소식통을 인용해 많은 경영진이 이번 주 후반 시진핑 주석과의 세션을 포함한 추가 고위급 회의가 예상되는 중국 개발 포럼(China Development Forum)에 참석하기 위해 베이징에 있다고 밝혔다.
왜 중요한가: 중국은 경제 둔화와 도널드 트럼프 대통령의 새로운 <a href="https://in.benzinga.com/news/global/25/03/44448798/china-ponders-export-limitations-to-quell-trumps-trade-onslaught" target="_blank" rel="noopener">미국 관세 역풍</a> 속에서 외국 자본을 유치하기 위한 노력을 강화했다.
올해 포럼에는 미국 기업이 가장 큰 그룹을 구성했지만, 소식통에 따르면 작년에 비해 미국 기업 CEO의 참석자 수가 줄어 국경 간 기업 관계에 대한 지속적인 경계를 시사한다고 보고서는 지적했다.
앞서 중국 대통령은 중국이 냉전 시대 소련과 같은 고립에 직면할 가능성에 대해 우려를 표명했다. 현재 진행 중인 무역 전쟁은 <a href="https://in.benzinga.com/25/03/44161587/is-china-apprehensive-of-losing-the-trade-war-to-the-us-china-could-get-isolated-like-moscow-fears-xi-jinping" target="_blank" rel="noopener">경제적 고립에 대한 두려움</a>을 고조시켰다.
투자자 레이 달리오는 이러한 어려움에도 불구하고 중국은 특히 인공지능과 로봇공학 분야에서 기술 발전의 <a href="https://in.benzinga.com/general/market-summary/25/03/44273552/ray-dalio-says-china-is-way-ahead-in-ai-and-robotics-us-lags-in-mass-production" target="_blank" rel="noopener">선두주자로 남아 있다고 말했다.</a>
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>의 도움을 받아 생성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

중국, 미국과 긴장 속 애플·화이자·일라이릴리 등 주요 기업 경영진과 만나..."계속 비즈니스 환경 개선할 것"

CNN 머니 공포·탐욕 지수는 전체 시장 심리의 개선을 나타냈으며 지난 금요일(14일) &#8220;공포&#8221; 영역에 있었다.
금요일 미국 증시는 혼조세를 보였으며, 다우존스 지수는 장중 150포인트 이상 하락했다. 그러나 지난주 동안에 미국 증시는 상승을 기록했다. S&amp;P 500 지수는 약 1.5% 상승하고, 다우 지수는 0.6% 상승, 나스닥 지수는 2.6% 상승했다.
트레이더들은 예상보다 저조한 소매판매와 러시아와 우크라이나 간의 평화 회담 가능성을 소화했다. 미국의 소매판매는 1월에 전월 대비 0.9% 감소하여 예상치 0.1% 감소를 하회했다.
사운드하운드 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) 주가는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 13F 공시에서 회사 지분을 청산했다고 밝힌 후 금요일에 28% 하락했다. 서브 로보틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>)는 수정된 13G 공시에서 엔비디아가 회사 지분을 보유하고 있지 않다고 나타난 후 주가가 40% 급락했다.
S&amp;P 500 지수 대부분 섹터는 금요일에 부정적인 마감세를 보였고, 헬스케어, 소비재, 유틸리티 섹터는 하락했다. 그러나 정보 기술과 통신 서비스 섹터는 전체 시장 추세에 반해 상승 마감했다.
다우존스는 금요일에 약 165포인트 하락한 44,546.08포인트로 마감했고, S&amp;P 500는 0.01% 하락한 6,114.63포인트, 나스닥 종합지수는 0.41% 상승한 20,026.77포인트로 마감했다.
투자자들은 오늘 메드트로닉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), 옥시덴탈 페트롤리엄(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>), 플루오르(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란? </h3>
공포·탐욕 지수는 현재 44.5이며 금요일에 &#8220;공포&#8221; 구역에 있었다. 이전 지수는 43.3이었다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다우 지수 150p 이상 하락했으나 주간 상승 기록: 투자 심리 개선, 탐욕 지수는 '공포' 영역

화요일(18일) 아침 미국 주식 선물이 상승하는 가운데, 오늘 투자자들의 주목을 받을 수 있는 주식들은 다음과 같다.
<ul>
<li>메드트로닉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>): 오늘 개장 전 실적을 발표할 예정이며, 주당순이익 1.36달러, 매출 83억 2천만 달러가 예상된다. 주식은 애프터마켓에서 0.7% 상승한 93.44달러에 거래되었다.</li>
<li>바이두 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>): 오늘 개장 전 실적을 발표할 예정이며, 주당순이익 1.78달러, 매출 45억 6천만 달러가 예상된다. 주식은 애프터마켓에서 0.3% 상승한 97.72달러에 거래되었다.</li>
<li>소후닷컴 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHU#NASDAQ">SOHU</a>): 4분기에 비GAAP 기준으로 1,500만 달러의 순손실을 기록했으며, 작년 같은 기간에는 1,100만 달러의 손실을 기록했다. 4분기 총 매출은 전년 대비 5% 감소한 1억 3,500만 달러로 집계되었다. 주식은 애프터마켓에서 1.6% 상승하여 14.90달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 보도</a>를 확인하세요.
<ul>
<li>옥시덴탈 페트롤리엄 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>): 주당순이익 70센트, 매출 70억 5천만 달러가 예상된다. 주식은 애프터마켓에서 0.6% 상승한 48.33달러에 거래되었다.</li>
<li>플루오르 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>): 오늘 개장 전 실적을 발표할 예정이며 주당순이익 77센트, 매출 44억 2천만 달러가 예상된다. 주식은 애프터마켓에서 0.9% 상승한 43.80달러에 거래되었다.</li>
</ul>
사진 제공: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 다소 개선되었음을 보여 주면서 화요일에는 &#8220;중립&#8221; 영역에 머물렀다.
화요일(19일) 미국 증시는 혼조세를 보였으며, 나스닥 지수는 약 1% 상승했다. 이는 투자자들이 우크라이나와 러시아 간의 상승하는 지정학적 우려를 과소평가했기 때문이다. 우크라이나는 러시아 도시에 미국산 미사일을 처음으로 발사했고, 블라디미르 푸틴 러시아 대통령은 잠재적 대응 시나리오를 확대하기 위해 핵무기 독트린을 조정했다.
엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) 주식은 오늘 발표될 분기 실적 보고서를 앞두고 화요일에 약 5% 상승했다. 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) 주식도 2% 상승했으며, 11월 들어서는 약 38% 상승했다.
월마트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) 주식은 회사가 긍정적인 분기 실적을 발표하고 전망을 상향 조정한 후 화요일에 약 3% 상승했다. 메드트로닉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)도 2분기 실적이 예상보다 좋았고 전망을 상향 조정했다.
경제지표 측면에서는 10월 미국 주택 착공 건수는 전월의 135만 3천 건에서 3.1% 감소한 113만 1천 건이었다. 10월 미국 건축 허가 건수는 0.6% 감소한 연간 1,416만 건을 기록했다.
S&amp;P 500 지수 대부분의 섹터가 긍정적으로 마감했으며, 에너지, 통신 서비스, 소비재 섹터가 가장 큰 상승폭을 기록했다. 그러나 산업재 섹터는 전체 시장 추세에 반하여 하락했다.
다우존스 지수는 화요일에 약 121포인트 하락한 43,268.94포인트로 마감했다. S&amp;P 500 지수는 0.40% 상승하여 5,916.98포인트로 마감했으며, 나스닥 종합 지수는 1.04% 상승한 18,987.47포인트로 마감했다.
투자자들은 오늘 타깃 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>), TJX 컴퍼니즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>), 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
공포·탐욕 지수는 현재 50.1의 지수를 기록하고 있으며 화요일에 &#8220;중립&#8221; 구역에 머물렀다. 이전 지수는 49.9였다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

TSLA

엔비디아 실적 발표 앞두고 나스닥 1% 상승: 투자심리 개선, 공포·탐욕 지수는 '중립' 영역

화요일(19일) 아침 미국 주식 선물이 상승하고 있는 가운데, 오늘 투자자들의 주목을 받을 수 있는 종목은 다음과 같다.
1. 월마트 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)
<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noopener">벤징가 프로</a> 데이터에 따르면 월가에서는 월마트 분기 주당순이익을 53센트, 매출은 1,677억 2천만 달러로 예상하고 있다. 주가는 애프터마켓에서 1.6% 상승한 85.44달러에 거래되었다.
2. 에이컴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>)
에이컴의 4분기 호실적을 발표했다. 분기 주당순이익은 1.27달러로 예상치 1.24달러를 상회했다. 그러나 매출은 41억 1천만 달러로 애널리스트 예상치 41억 4천만 달러에 미치지 못했다. 주가는 애프터마켓에서 1.2% 하락한 107.80달러에 거래되었다.
3. 로우스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>)
애널리스트들은 오늘 개장 전 실적을 발표할 로우스의 분기 주당순이익은 2.82달러, 매출은 199억 4천만 달러로 예상하고 있다. 주가는 애프터마켓에서 0.1% 상승한 272.10달러에 거래되었다.
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 커버리지</a>를 확인하세요.
4. 심보틱 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>)
심보틱은 월요일(18일) 4분기 호실적을 발표했다. 또한 2025회계연도 1분기 예상 매출은 4억 9,500만 달러~5억 1,500만 달러로 예상하면서 예상치 4억 9,573억 달러를 상회했고, 조정 EBITDA는 2,700만 달러~3,100만 달러 범위로 예상했다. 주가는 애프터마켓에서 26.3% 상승한 38.60달러에 거래되었다.
5. 메드트로닉 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)
애널리스트들은 오늘 개장 전 실적을 발표할 메드트로닉의 분기 주당순이익은 1.25달러, 매출은 82억 7천만 달러를 예상하고 있다. 주가는 애프터마켓에서 0.2% 상승한 87.74달러에 거래되었다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/crypto/blockchain/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C%EC%9D%98-%EC%95%84%ED%81%AC-%EC%9D%B8%EB%B2%A0%EC%8A%A4%ED%8A%B8-500%EC%A1%B0-%EB%8B%AC%EB%9F%AC-%EA%B7%9C%EB%AA%A8-rwa-%ED%86%A0%ED%81%B0%ED%99%94-%EC%8B%9C/" target="_blank" rel="noopener">캐시 우드의 아크 인베스트, 500조 달러 규모 RWA 토큰화 시장에 낙관적</a>
이미지 출처: Wikimedia Commons
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

화요일 주목해야 할 주식: 월마트, 에이컴, 로우스, 심보틱 및 메드트로닉

CNN 머니 공포·탐욕 지수는 전체 시장 심리가 추가로 하락했음을 보여주었고, 월요일에 &#8220;중립&#8221; 영역에 머물렀다.
월요일(18일) 미국 주식은 혼조세를 보인 가운데 나스닥 지수는 세션 중 100포인트 이상 상승했다. 이는 도널드 트럼프 대통령 당선자의 <a href="https://www.benzinga.com/markets/equities/24/11/42028797/tesla-soars-over-5-in-overnight-trading-as-trump-administration-reportedly-seeks-to-ease-fsd-norms" target="_blank" rel="noopener">자율주행차 규제 완화 전망</a> 보도에 따라 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) 주식이 5.6% 급등하면서 나스닥도 오른 것이다.
미국 증시는 지난주 동안 하락을 기록했다. S&amp;P 500 지수는 2.1% 하락했으며, 나스닥 종합 지수는 약 3.2% 하락했다. 30개 종목으로 구성된 다우존스 지수는 1.2% 하락했다.
어닝 시즌과 관련해서는 S&amp;P 500 기업의 약 93%가 분기 실적을 발표했으며, 그중 약 74%가 실적 예상치를 상회했다.
경제지표 측면에서는 NAHB/웰스파고 주택 시장 지수가 11월에 46으로 상승하면서 7개월 만에 가장 높은 수치를 기록했다. 비교하자면 10월에는 43이었다.
S&amp;P 500의 대부분의 섹터가 긍정적으로 마감했으며, 에너지, 통신 서비스 및 소비재 섹터가 월요일에 가장 큰 상승폭을 기록했다. 그러나 산업재 섹터는 전체 시장 추세와 달리 하락세로 마감했다.
월요일 다우존스 지수는 약 55포인트 하락하여 43,389.60포인트로 마감했다. S&amp;P 500 지수는 0.39% 상승한 5,893.62포인트, 나스닥 종합 지수는 0.60% 상승한 18,791.81포인트로 마감했다.
투자자들은 오늘 월마트(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), 로우스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), 그리고 메드트로닉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)의 실적 발표를 기다리고 있다.
<h3>CNN 비즈니스 공포·탐욕 지수란?</h3>
CNN 공포·탐욕 지수는 현재 50.1이고 월요일에 &#8220;중립&#8221; 영역에 머물렀다. 이전 수치는 51.1이었다.
공포·탐욕 지수는 현재 시장 심리를 측정하는 지표다. 공포가 높을수록 주가에 압력을 가하고, 탐욕이 높을수록 주가를 상승시킨다는 전제를 바탕으로 한다. 이 지수는 동일한 가중치를 가진 7가지 지표를 기준으로 계산된다. 지수의 범위는 0에서 100까지이며 0은 최대 공포를, 100은 최대 탐욕을 나타낸다.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/3%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81-%EB%B0%9C%ED%91%9C-%EC%95%9E%EB%91%94-%EC%97%94%EB%B9%84%EB%94%94%EC%95%84-%EC%98%88%EC%83%81%EC%B9%98-%EC%83%81%ED%9A%8C-%EC%8B%9C-140%EB%8B%AC%EB%9F%AC/" target="_blank" rel="noopener">3분기 실적 발표 앞둔 엔비디아, &#8220;예상치 상회 시 140달러 이상으로 오를 것&#8221;</a>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

테슬라 오르면서 나스닥 100p 이상 상승: 투자심리 하락, 공포·탐욕 지수는 '중립' 영역에 머물러

화요일 오전 (현지 시간 기준) 미국 주식 선물이 약간 높게 거래되면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다:
<ul>
<li>월스트리트는 로우스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>)가 개장 전 240억 1천만 달러의 매출과 주당 3.99달러의 분기 이익을 보고할 것으로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard">벤징가 프로(Benzinga Pro)</a>의 데이터에 따르면 로우스의 주가는 시간외 거래에서 0.2% 하락한 242.70달러를 기록했다.</li>
<li>팔로알토 네트웍스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)는 <a href="https://www.benzinga.com/news/earnings/24/08/40449958/palo-alto-networks-q4-earnings-revenue-beat-eps-beat-strong-guidance-500m-added-to-buyback-and-more">예상을 뛰어넘는</a> 4분기 실적을 보고하고 강력한 지침을 발표했다. 팔로알토의 이사회는 자사주 매입을 위해 추가로 5억 달러를 승인했으며, 이로써 회사의 남은 자사주 매입 승인 금액은 최대 10억 달러로 늘어났다. 팔로알토의 주가는 시간외 거래에서 1.9% 상승한 350.00달러를 기록했다.</li>
<li>분석가들은 메드트로닉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)이 78억 9천만 달러의 매출과 분기 이익을 주당 1.20달러로 기록할 것으로 예상한다. 회사는 시장이 열리기 전에 실적을 발표할 예정이다. 메드트로닉의 주가는 시간외 거래에서 0.4% 상승한 85.17달러를 기록했다.</li>
</ul>
여기에서 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener" data-google-interstitial="false">프리마켓 시황</a>을 확인하세요.
<ul>
<li>플루언트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNT#NASDAQ">FLNT</a>)는 월요일 예상보다 나쁜 2분기 재무실적을 발표했다. 플루언트의 주식은 시간외 거래에서 16.3% 하락한 2.51달러를 기록했다.</li>
<li>분석가들은 알콘(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>)이 시장 마감 후 매출 25억 2천만 달러, 주당 73센트의 분기 이익을 공시할 예정이다. 알콘의 주가는 시간외 거래에서 0.01% 상승한 96.27달러를 기록했다.</li>
</ul>
Midjourney를 사용하여 제작된 이미지
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Medtronic

뉴스

에 대한 최신 뉴스 Medtronic (NYSE:MDT) 주식

월요일, 3월 24, 2025

화요일, 2월 18, 2025

수요일, 11월 20, 2024

화요일, 11월 19, 2024

화요일, 8월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌